التفاصيل البيبلوغرافية
| العنوان: |
Targeting metabolic pathways to counter cancer immunotherapy resistance. |
| المؤلفون: |
Agarwala, Yuki1,2 (AUTHOR), Brauns, Timothy A.1 (AUTHOR), Sluder, Ann E.1 (AUTHOR), Poznansky, Mark C.1 (AUTHOR), Gemechu, Yohannes1 (AUTHOR) yhailu@mgh.harvard.edu |
| المصدر: |
Trends in Immunology. Jul2024, Vol. 45 Issue 7, p486-494. 9p. |
| مصطلحات موضوعية: |
*IMMUNE checkpoint inhibitors, *IMMUNOTHERAPY, *TREATMENT effectiveness, *CHIMERIC antigen receptors, *THERAPEUTICS |
| مستخلص: |
Metabolic modifiers can be efficacious in improving immune cell infiltration for various immunotherapeutic approaches, including immune checkpoint inhibitors, chimeric antigen receptor T cells, and cancer vaccines. Combination treatments might have synergistic effects. To accelerate the possible application of these drugs in the clinic, we advocate for further and robust research on the effect of metabolic modifiers on cancer and immune cells in the tumor microenvironment, especially considering the intra- and inter-tumor metabolic heterogeneity among patients. The identification of reliable serum biomarkers will be pivotal for accurately determining the efficacy of drugs in clinical trials; indeed, the therapeutic effects may be limited to specific patient subpopulations. Personalized therapeutic approaches based on specific metabolic modifiers might be administered alongside immunotherapies in a timeframe that is tailored to any given patient. Known for decades, cancer cells exhibit dysregulated energetics to enable growth in nutrient-deprived environments. Recent findings show that targeting these metabolic pathways can stimulate antitumor immunity within the tumor microenvironment. Combining metabolic modifiers with immunotherapies is a promising approach to overcoming cancer immunotherapeutic resistance. Immunotherapies have revolutionized the treatment of certain cancers, but challenges remain in overcoming immunotherapy resistance. Research shows that metabolic modulation of the tumor microenvironment can enhance antitumor immunity. Here, we discuss recent preclinical and clinical evidence for the efficacy of combining metabolic modifiers with immunotherapies. While this combination holds great promise, a few key areas must be addressed, which include identifying the effects of metabolic modifiers on immune cell metabolism, the putative biomarkers of therapeutic efficacy, the efficacy of modifiers on tumors harboring metabolic heterogeneity, and the potential development of resistance due to tumor reliance on alternative metabolic pathways. We propose solutions to these problems and posit that assessing these parameters is crucial for considering the potential of metabolic modifiers in sensitizing tumors to immunotherapies. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |